Hematology Translational Lab (Storek-Khan Lab)
HMRB-336F, 3330 Hospital Drive NW, Calgary AB T2N4N1
Phone: 403-2207671; 403-2103935
Fax: 403-2108176

Soluble Receptor Report – Luminex 2-plex Panel

ORDER DETAILS

Patient Name	HELIX, Onco		
Medical Record#	11111-55555	**Physician**	Dr. XXXXXX-YYYY
Date of Birth	XX-Mar-78	**Organization**	FMC
Gender	Male	**Address**	Calgary AB
Diagnosis	?HLH (4/8 criteria match)		

SPECIMEN AND TEST

Specimen Type	Frozen Serum	**Date Received**	16-Apr-2020	**Report Status**	Final
Specimen ID	AA-AB-553565	**Analysis Date**	16-Apr-2020	**Report Date**	17-Apr-2020

REPORT SUMMARY

No.	Soluble Receptor	Results (pg/mL)		
1	sCD25/sIL2R-alpha	**11032.35**	*Very High*	

No.	Soluble Receptor	Results (ng/mL)		
2	sCD163	**4255.25**	*Very High*	

Code	Label	Definition	Description
	ND	Not detected	Value was not detected in the assay
	Very Low	< Lower limit of detection (LLOD)	Value smaller than the lower limit of detection
	Low	0-30th percentile	30% of the reference samples have values less than the cutoff
	Moderate	30th-70th percentile	40% of the reference samples fall in this range
	High	> 70th percentile	Value higher than 70% of the reference samples.
	Very High	> Upper limit of detection (ULOD)	Higher than upper limit of detection

COMPARISON WITH PREVIOUS RESULTS

No.	Soluble Receptor	Date Results	Date Results	Date Results
1	sCD25/IL2R-alpha (pg/mL)			
2	sCD163 (ng/mL)			

COMMENT

First specimen received for this patient. The findings are suggestive of HLH. Clinical correlation is required.

Patient	Medical Record#	Diagnosis	Report Date	Report Status
HELIX, Onco	11111-55555	?HLH (4/8 criteria match)	17-Apr-2020	Final

METHOD

Multiplex immunoassay using Luminex xMAP (multi-analyte profiling) technology was performed on the submitted serum sample to quantitate sIL2Ralpha and sCD163 protein targets simultaneously using Luminex instrument. The assay is based on the principle of sandwich ELISA (Enzyme Linked Immunosorbent Assay). A 5-parameter (5-P) logistic regression model was generated from the mean florescence intensity(MFI) detected by the Luminex instrument and the known standards for each analyte. Standards with a serial dilution of 1:3 were used for generating the model. Criteria of acceptance of the model are R2 value >95%, percent recovery of each point of the standard curve < 30%, and percent CV of duplicates <30%. MFI values of the unknown samples were compared to the 5-P logistic regression curve of each Soluble Receptor to calculate the levels.
Interpretation of the results (low, moderate or high) was based on the comparison of the Soluble Receptor levels generated from 70 healthy individuals using the same Soluble Receptor panel in Hematology Translational Lab(HTL). Details of lower and upper limit of detection along with the healthy range can be provided upon request.
Test performance characteristics for this laboratory validated test has been determined by the College of Physicians and Surgeons of Alberta (CPSA) accredited laboratory.

DISCLAIMER

This report is based on the assumption that the sample received from the individual noted by the unique identifiers and has not been contaminated with that of another individual prior to receipt at the Hematology Translational Lab(HTL). It is assumed that the serum sample has been processed by following the strict guidelines recommended by HTL.
Absolute value of the Soluble Receptor levels can vary based on kit used and the lab in which the assay is performed. Variability in the absolute value of the Soluble Receptor levels between different runs was less than 25%.
Results from this panel should be interpreted in the context of all clinical, biochemical, genetic and other molecular data.

REVIEW AND APPROVAL

Report Reviewed, Verified and Approved by

Director

Medical Director

~~~~~~~~~~~~~~~~~~~~~~~~~ **End of Report** ~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~